A study from the American Society of Hematology (ASH) Annual Meeting and Exposition presented by lead investigator Adam Lamble, MD, Attending Physician, Assistant Professor of Pediatrics, Cancer & Blood Disorders Center, High-Risk Leukemia Program, Leukemia & Lymphoma Program, Seattle Children's Hospital, was the largest investigation of TP53 mutations in pediatric patients with acute myeloid leukemia (AML). "A big effort at the Children's Oncology Group, and where my work is, is trying to see if we can better define, or identify those patients that would benefit from a stem cell transplant," Lamble said in an interview with HCPLive. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more